OBJECTIVE: Clinical management of bipolar disorder (BPD) patients during pregnancy is a major challenge. The high risk of bipolar depression during pregnancy encourages consideration of lamotrigine (LTG). We therefore compared recurrence risks among pregnant women with BPD treated with LTG to those discontinuing mood stabilizer therapies. METHODS: We compared risks and weeks to new DSM-IV illness-episodes among 26 initially clinically stable pregnant women diagnosed with DSM-IV BPD who continued LTG treatment to those discontinuing all mood stabilizer treatment during pregnancy. RESULTS: The risk of new illness-episodes with LTG was 30% versus 100% after discontinuing mood stabilizers, and survival-computed time-to-25%-recurrence was 28.0 versus 2.0 weeks (chi(2 )=17.3, p < 0.0001; hazard ratio = 12.1; 95% confidence interval = 1.6-91.7). CONCLUSIONS: Discontinuing mood stabilizer treatment presents high risks of illness-recurrence among pregnant women diagnosed with BPD. LTG may afford protective effects in pregnancy, and its reported fetal safety compares favorably to other agents used to manage BPD.
OBJECTIVE: Clinical management of bipolar disorder (BPD) patients during pregnancy is a major challenge. The high risk of bipolar depression during pregnancy encourages consideration of lamotrigine (LTG). We therefore compared recurrence risks among pregnant women with BPD treated with LTG to those discontinuing mood stabilizer therapies. METHODS: We compared risks and weeks to new DSM-IV illness-episodes among 26 initially clinically stable pregnant women diagnosed with DSM-IV BPD who continued LTG treatment to those discontinuing all mood stabilizer treatment during pregnancy. RESULTS: The risk of new illness-episodes with LTG was 30% versus 100% after discontinuing mood stabilizers, and survival-computed time-to-25%-recurrence was 28.0 versus 2.0 weeks (chi(2 )=17.3, p < 0.0001; hazard ratio = 12.1; 95% confidence interval = 1.6-91.7). CONCLUSIONS: Discontinuing mood stabilizer treatment presents high risks of illness-recurrence among pregnant women diagnosed with BPD. LTG may afford protective effects in pregnancy, and its reported fetal safety compares favorably to other agents used to manage BPD.
Authors: Angelica L Kloos; Abigail Dubin-Rhodin; Jillan Cantor Sackett; Thomas A Dixon; Ronald A Weller; Elizabeth B Weller Journal: Curr Psychiatry Rep Date: 2010-04 Impact factor: 5.285
Authors: Meera Viswanathan; Jennifer Cook Middleton; Alison M Stuebe; Nancy D Berkman; Alison N Goulding; Skyler McLaurin-Jiang; Andrea B Dotson; Manny Coker-Schwimmer; Claire Baker; Christiane E Voisin; Carla Bann; Bradley N Gaynes Journal: Psychiatr Res Clin Pract Date: 2021-05-04
Authors: D Jeffrey Newport; Page B Pennell; Martha R Calamaras; James C Ritchie; Melanee Newman; Bettina Knight; Adele C Viguera; Joyce Liporace; Zachary N Stowe Journal: Pediatrics Date: 2008-06-30 Impact factor: 7.124
Authors: Grace A Masters; Linda Brenckle; Padma Sankaran; Sharina D Person; Jeroan Allison; Tiffany A Moore Simas; Jean Y Ko; Cheryl L Robbins; Wendy Marsh; Nancy Byatt Journal: Gen Hosp Psychiatry Date: 2019-10-22 Impact factor: 3.238
Authors: Clare L Taylor; Robert Stewart; Jack Ogden; Matthew Broadbent; Dharmintra Pasupathy; Louise M Howard Journal: BMC Psychiatry Date: 2015-04-17 Impact factor: 3.630